presentation_file_5172a0a5-8b08-497e-8466-061bac1008a6

7/28/2019 presentation_file_5172a0a5-8b08-497e-8466-061bac1008a6

1/10

4/20/2013 1

Click to edit Master title style

4/20/2013 1


2/10

4/20/2013 2

1. $ 1 Billion to get a drug to market

2. 15 years to develop and get approved

3. 20 year Patent Life = 5 years of protected sales

Novel Target

Validation

LeadOptimization

Pre ClinicalDevelopment

Clinical

Development

How we Help

1. Lower Cost(less Man-hours)

2. Reduce Failure Rate

3. Time Saver(Extends Patent life)

4. Increase Probability

of Success


3/10

4/20/2013 3

1. Novel Target

Validation

2. Lead

Optimization

3. Pre-Clinical

Development

4. Clinical

Development

FDA Approval

5. Sales $$$

Billion Dollar

Market

Develop Compound

Identify Indication

Safety/Tolerability

Feasibility

Animal Testing

Formulation

Clinical Trials

IND Filing

Compound

Repositioning

2 -4 years

75% Failure Rate

10% of cost

1-3 years

80% Failure Rate

15% of cost

1-2 years

67% Failure Rate

25% of cost

6- 8 years

80% Failure Rate

50 % of cost

15 years

$1 Billion

Success = 1/10,000

nFlow

Chemically Aware

nFlow

Chemically Aware

nFlow

nFlow

Chemically Aware

Compound Repositioning

Stage Outcomes StatsProduct

InteractionsAfter BlueAtom

1-3 Months

60 % Failure Rate

5 % of cost

6-9 Months

65 % Failure Rate

7.5 % of cost

5 -12 Months

52 % Failure Rate

12.5% of cost

(Potential)

10 years

$750 Million

Success =

1500/10,000

6- 8 years

80% Failure Rate

75 % of cost


4/10

4/20/2013 4

Differentiation Result Stage Interaction

Chemical Structure Search

(Optical Structure Recognition)

Compound

Likeness/Competitive

Stage 1

Compound Repositioning Therapeutic Indication based

on best probability

Stage 2 4

Technology: Database Driven Application that sits on MS SharePoint (Industry leading

collaboration tool)

Differentiation Result Stage Interaction

Business Process Workflow

Automation

Automates

Safety/Tolerability/Feasibility

modeling and lab data readout

Stage 2 & 3

Competitive Intelligence Uses Publicly Available dataincluding FDA and Publication

sites

Stage 2

Consensus Scoring Identifies Most Viable

compounds for targeted

indications

Stage 2

Technology: Data Warehouse Driven Dashboard

Year 3 revenues = $7,382,500

Customer Count = 10 new | 13 renewals

Year 3 revenues = $1,614,375 (net discounts)

Customer Count = 32 new | 40 renewals


5/10

4/20/2013 5

Product Company SubStructure

Search

Compound

Reposition

Compound

Screening

Deficiencies

Chem4SharePoint Scigillence Yes No No Inefficient, No integration

with other products

Search Genius Perkin Elmer Yes No No High Priced tag

SharePoint WebPart Accelrys No No No Static searches, inconclusive

results

Key Points: Compound Screening and Repositioning,

Third party integration, Patented Algorithm

Key Points: Consensus Scoring, fully integrated to

environment

Product Company Assay

Workflow

Consensus

Scoring

Third Party/Lab

Integration

Deficiencies

In-House

Application

Large pharma No No Specific to

products owned

by company

High development costs,

development dependent on

Success

HEOS Accelrys Yes No No Service based, Web only


6/10

4/20/2013 6

15 % Big Pharma (GSK, Merck, Pfizer, J&J)

9% Medium Pharma ( Targacept, Allergan, Etc.)

76% Small Pharma (Start-ups, emerging)

Roche

Genentech

Eisai

Cleveland Clinic

Demo

Complete

or potential

lead

H3Biomed

AMBIn discussions

nFlow

Chemically Aware

ASINEX In discussionsnFlow

Chemically Aware

nFlow

Chemically Aware

% Type Components

20 Direct Sales Sales

Training

Implementation (services)80 Channel Partner (Perkin Elmer, Pharmica, Dell)


7/10

4/20/2013 7

POC in non-NNR/CNS pharmaceutical company

Acceptance of Grant submissions by NIH and HHS for continued

development of product capabilities

Collaboration Partnerships with complementary product integrate

additional functionality

Funding by investor to retain and hire key personnel


8/10

4/20/2013 8

Developers with Mobility and Cloud experience

Collaboration partners to validate results and peer review

product capabilities

Wide adoption of the technologies which will enable faster

results and streamline the products


9/10

4/20/2013 9

Industry is researching the problem for resolution

Large academia pool of computational chemists and biological

modelers to pull from

Federal Government funding opportunities of this nature to

solve the cost, time and success of drug discovery

Application goes beyond drugs to auto, biofuel and bioenergy

industries


10/10

4/20/2013 10

Name Position Experience

Miles Romello

CISSP, CISRC

CEO/CTO 20 Yrs. IT (Hands on & leadership)

Wachovia (Corporate Information Security Manager)

Targacept (Sr. Director Information Technology)

Former CEO for Startup Internet Caf (90s)

ChandraHolcomb VP Operations 15 years in IT leadership and operationsTargacept

Womble Carlyle

Litera Corp.

Kartik

Tallapragada

Phd Candidate

Software

Development

Masters in Information Systems

Innovator of Blue Atom Technology

10 years Development Experience

PublishedDr. David

Kombo, Phd

Computationa

l Chemistry

23 years Life Sciences

Published

Tied to numerous patents

Mauri Hodges

CPA, CCP

Board

Chairman

Executive in Targacept for 15 years

Former CEO for software development company

Experience with start-up companies, venture funding, IPO

and acquisitions

presentation_file_5172a0a5-8b08-497e-8466-061bac1008a6

Documents